Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether there were differences in clinical characteristics, response, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306303/
https://www.ncbi.nlm.nih.gov/pubmed/32647793
http://dx.doi.org/10.1097/HS9.0000000000000363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306303/
https://www.ncbi.nlm.nih.gov/pubmed/32647793
http://dx.doi.org/10.1097/HS9.0000000000000363

Ejemplares similares